

World Journal of *Gastroenterology*

World J Gastroenterol 2024 March 28; 30(12): 1644-1779



EDITORIAL

- 1644** Interaction between diet and genetics in patients with inflammatory bowel disease
Magro DO, Sassaki LY, Chebli JMF
- 1651** Pediatric stricturing Crohn's disease
Boscarella A, Bramuzzo M
- 1655** Gut microbiota and female health
Wang MY, Sang LX, Sun SY
- 1663** Multiparametric ultrasound as a new concept of assessment of liver tissue damage
Peltec A, Sporea I
- 1670** Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope
Giri S, Sahoo J

OPINION REVIEW

- 1676** New direction for surgery: Super minimally invasive surgery
Linghu EQ

REVIEW

- 1680** Liquid biopsy for gastric cancer: Techniques, applications, and future directions
Díaz del Arco C, Fernández Aceñero MJ, Ortega Medina L

MINIREVIEWS

- 1706** Endoscopic treatment of scarred polyps with a non-thermal device (Endorotor): A review of the literature
Zaghloul M, Rehman H, Sansone S, Argyriou K, Parra-Blanco A

ORIGINAL ARTICLE**Retrospective Study**

- 1714** Predictive value of red blood cell distribution width and hematocrit for short-term outcomes and prognosis in colorectal cancer patients undergoing radical surgery
Peng D, Li ZW, Liu F, Liu XR, Wang CY
- 1727** Assessing recent recurrence after hepatectomy for hepatitis B-related hepatocellular carcinoma by a predictive model based on sarcopenia
Peng H, Lei SY, Fan W, Dai Y, Zhang Y, Chen G, Xiong TT, Liu TZ, Huang Y, Wang XF, Xu JH, Luo XH

- 1739 Treatment patterns and survival outcomes in patients with non-metastatic early-onset pancreatic cancer

Zhang LT, Zhang Y, Cao BY, Wu CC, Wang J

Clinical Trials Study

- 1751 Early proactive monitoring of DNA-thioguanine in patients with Crohn's disease predicts thiopurine-induced late leucopenia in NUDT15/TPMT normal metabolizers

Yang T, Chao K, Zhu X, Wang XD, Chan S, Guan YP, Mao J, Li P, Guan SX, Xie W, Gao X, Huang M

Basic Study

- 1764 ALKBH5 suppresses autophagic flux *via* N6-methyladenosine demethylation of ZKSCAN3 mRNA in acute pancreatitis

Zhang T, Zhu S, Huang GW

LETTER TO THE EDITOR

- 1777 Hepatic recompensation according to Baveno VII criteria *via* transjugular intrahepatic portosystemic shunt

Shaaban HE, Abdellatef A, Okasha HH

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Tamara Vorobjova, PhD, Academic Research, Associate Professor, Department of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu 51014, Estonia. tamara.vorobjova@ut.ee

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG's CiteScore for 2021 is 8.3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Yu-Xi Chen*; Production Department Director: *Xiang Li*; Cover Editor: *Jia-Ru Fan*.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF

Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou-Bao Liu (Biliary Tract Disease)

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

March 28, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

PUBLISHING PARTNER

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University
Biliary Tract Disease Institute, Fudan University

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

POLICY OF CO-AUTHORS

<https://www.wjgnet.com/bpg/GerInfo/310>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

PUBLISHING PARTNER's OFFICIAL WEBSITE

<https://www.shca.org.cn>
<https://www.zs-hospital.sh.cn>



Basic Study

ALKBH5 suppresses autophagic flux via N6-methyladenosine demethylation of ZKSCAN3 mRNA in acute pancreatitis

Tao Zhang, Shuai Zhu, Geng-Wen Huang

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: SeyedAlinaghi S, Iran

Received: November 11, 2023

Peer-review started: November 11, 2023

First decision: January 24, 2024

Revised: February 3, 2024

Accepted: March 6, 2024

Article in press: March 6, 2024

Published online: March 28, 2024



Tao Zhang, Shuai Zhu, Geng-Wen Huang, Department of General Surgery, Xiangya Hospital, Central South University, Changsha 410005, Hunan, China.

Tao Zhang, Shuai Zhu, Geng-Wen Huang, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410005, Hunan, China.

Corresponding author: Shuai Zhu, MD, PhD, Surgeon, Department of Pancreatic Surgery, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410005, Hunan Province, China. zhushuai@csu.edu.cn

Abstract

BACKGROUND

Increasing evidence has demonstrated that N6-methyladenosine (m⁶A) RNA modification plays an essential role in a wide range of pathological conditions. Impaired autophagy is a critical hallmark of acute pancreatitis (AP).

AIM

To explore the role of the m⁶A modification of ZKSCAN3 in the regulation of autophagy in AP.

METHODS

The AP mouse cell model was established by cerulein-treated mouse pancreatic acinar cells (MPC-83), and the results were confirmed by the levels of amylase and inflammatory factors. Autophagy activity was evaluated by specific identification of the autophagy-related microstructure and the expression of autophagy-related genes. ZKSCAN3 and ALKBH5 were knocked down to study the function in AP. A m⁶A RNA binding protein immunoprecipitation assay was used to study how the m⁶A modification of ZKSCAN3 mRNA is regulated by ALKBH5.

RESULTS

The increased expression of amylase and inflammatory factors in the supernatant and the accumulation of autophagic vacuoles verified that the AP mouse cell model was established. The downregulation of LAMP2 and upregulation of LC3-II/I and SQSTM1 demonstrated that autophagy was impaired in AP. The expression of ZKSCAN3 was upregulated in AP. Inhibition of ZKSCAN3 increased the expression of LAMP2 and decreased the expression of the inflammatory factors, LC3-II/I and SQSTM1. Furthermore, ALKBH5 was upregulated in AP. Knockdown of ALKBH5 downregulated ZKSCAN3 expression and restored

decreased autophagic flux in AP. Notably, the bioinformatic analysis revealed 23 potential m⁶A modification sites on *ZKSCAN3* mRNA. The m⁶A modification of *ZKSCAN3* mRNA was significantly decreased in AP. Knockdown of *ALKBH5* increased the modification of *ZKSCAN3* mRNA, which confirmed that *ALKBH5* upregulated *ZKSCAN3* expression in a m⁶A-dependent manner.

CONCLUSION

ALKBH5 inhibits autophagic flux through m⁶A demethylation of *ZKSCAN3* mRNA in AP, thereby aggravating the severity of the disease.

Key Words: Acute pancreatitis; Autophagy; *ZKSCAN3*; N6-methyladenosine; *ALKBH5*

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Acute pancreatitis (AP) is a common emergency in digestive system. Impaired autophagy is one of important pathogenic mechanisms of AP, however, its regulatory mechanism remains unclear. N6-methyladenosine modification and *ZKSCAN3* are crucial regulatory factors of autophagy, but their roles in AP are not well-defined. This study confirmed that the demethylase *ALKBH5* can inhibit autophagy flux by upregulating *ZKSCAN3*, thereby exacerbating the inflammatory severity of AP. The findings of this study provided new insights into the autophagy regulation mechanism and offered a novel direction for early intervention in AP.

Citation: Zhang T, Zhu S, Huang GW. *ALKBH5* suppresses autophagic flux via N6-methyladenosine demethylation of *ZKSCAN3* mRNA in acute pancreatitis. *World J Gastroenterol* 2024; 30(12): 1764-1776

URL: <https://www.wjgnet.com/1007-9327/full/v30/i12/1764.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v30.i12.1764>

INTRODUCTION

Acute pancreatitis (AP) is one of the most common digestive emergencies. The global prevalence and incidence of AP are approximately 76/100000 and 34/100000, respectively, and the number of new cases is increasing at an annual rate of 3% [1-3]. With the progression of therapeutic concepts and interventions, the prognosis of AP has significantly improved. However, due to the unclear pathogenesis of AP, clinicians are still unable to effectively intervene specifically in local or systemic inflammation. The pathogenesis of AP is complex and multifactorial and induces significant and sustained pathological disruption[4,5]. Therefore, further study of the mechanism underlying the progression of AP will provide insight into the development of future therapeutic strategies.

Autophagy is a highly conserved catabolic process in which abnormal biomolecules and organelles are degraded and degradation products are recycled. Autophagy plays an important role in maintaining cellular homeostasis. The entire autophagy process is defined as autophagic flux, and disrupted integrity of the process is called impaired autophagy[6]. Studies have shown that impaired autophagy plays an important role in the development of various diseases, such as neurodegeneration, inflammation, infection, tumors, and metabolic disorders[7-9]. In recent years, the important role of autophagy in AP has been gradually recognized. The basal level of autophagy in the mouse exocrine pancreas is significantly greater than that in the endocrine pancreas and other organs[10]. In experimental pancreatitis, interfering with the expression of upstream regulatory molecules or autophagy-related genes can induce inflammatory changes in exocrine pancreatic cells[11]. Impaired autophagy in AP manifests as activation of the initial stage but blockade of the degradation stage, resulting in harmful factors such as abnormal zymogen granules and disrupted organelles that cannot be effectively degraded[10]. Although impaired autophagy can mediate abnormal zymogen activation, inflammation, and cell death in pancreatic acinar cells[12], the specific regulatory mechanism involved is still unclear.

ZKSCAN3 is a zinc finger DNA-binding protein that simultaneously contains KRAB and SCAN domains; it is also a recognized inhibitory factor of autophagy[13,14]. Studies have shown that *ZKSCAN3* can inhibit the transcription of numerous autophagy-related genes, such as *LC3* and *WIP1*, thereby suppressing a series of autophagy steps in various diseases[15,16]. However, the role of *ZKSCAN3* in autophagy in AP has not yet been determined.

The N6-methyladenosine (m⁶A) modification of RNA plays an important role in the autophagy regulatory network. This process is reversible and involves mainly methyltransferases, demethylases, and methylated RNA-binding proteins [17,18]. *ALKBH5* is a crucial demethylase that plays a key role in various diseases[19,20]. In ovarian cancer, the overexpression of *ALKBH5* promotes the formation of the BCL-2-Beclin1 complex, and inhibits autophagy[21]. In silica-related pneumonia, *ALKBH5* can mediate autophagic flux blockade through the Slamf7 pathway[22]. However, in myocardial ischemia-reperfusion injury, *ALKBH5* plays a role in promoting autophagic flux[23]. Although the role of m⁶A modification in impairing autophagy has been demonstrated in various tumors and inflammatory diseases, there is no experimental research on m⁶A modification in AP. Recent bioinformatics studies have shown that decreased m⁶A levels are related to the occurrence of severe AP[24], but whether this change is related to *ALKBH5*-mediated impaired autophagy in AP is unclear.

Clarifying the regulatory mechanism of autophagy in AP is crucial for early intervention. However, research on the autophagy and its regulatory mechanism in AP has not been illustrated. Therefore, in this article we aimed to explore the role and mechanism of action of *ALKBH5* in *ZKSCAN3* regulated autophagy. We verified the results at the cellular level through a series of molecular biology experiments, which provided a novel perspective on the research of pathogenesis and molecular mechanism of AP and highlighted new targets for therapeutic intervention.

MATERIALS AND METHODS

Cell culture

Mouse pancreatic acinar cells (MPC-83) were cultured in RPMI-1640 supplemented with 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin in a 37 °C incubator with 5% CO₂. The control groups were not treated, and the AP groups were pretreated with cerulein (10 nM) for 24 h.

Cell transfection

MPC-83 cells were seeded in 6-well plates and maintained at 37 °C and 5% CO₂. *ALKBH5* and *ZKSCAN3*-siRNA (50 nM) (RiboBio, Gunagzhou, China) were transfected into MPC-83 cells. After 48 h of transfection, the cells were treated with cerulein (10 nM) for 24 h.

Quantitative real-time RT-PCR

Total RNA was extracted from cells using the TRIzol method. All mRNAs were reverse transcribed using the PrimeScript™ RT reagent Kit (Perfect Real Time) (TaKaRa, Kyoto, Japan). Reverse transcription and quantitative real-time RT-PCR were performed with SYBR® Premix Ex Taq™ (TaKaRa, Kyoto, Japan). The results were normalized to that of β -actin and calculated *via* the relative quantification ($2^{-\Delta\Delta C_t}$) method. The primers used were purchased from Sangon Company (Table 1).

ELISA

The supernatant of MPC-83 cells was collected. The levels of interleukin 6 (IL)-6, IL-1 β , and tumor necrosis factor (TNF)- α were assessed using ELISA kits (Neobioscience, Shenzhen, China).

Western blot

Cell lysates were prepared using lysis buffer composed of 50 mmol/L Tris-HCl, 150 mmol/L NaCl, 0.5% sodium deoxycholate, 0.1% SDS, and 1% NP-40. The lysates were centrifuged to collect the supernatants. An equal amount of protein was denatured in SDS sample buffer and separated on 8% or 10% polyacrylamide gels based on the molecular weight of the target proteins. The separated proteins were then transferred to a PVDF membrane. The membranes were blocked with 5% nonfat milk in TBST (TBS containing 0.05% Tween 20), incubated with primary antibodies, and subsequently incubated with secondary antibodies conjugated to alkaline phosphatase. Protein expression was detected by chemiluminescence. The antibodies used were against *ALKBH5* (ab195377, Abcam, Britain), *ZKSCAN3* (ab223477, Abcam, Britain), *LC3* (Proteintech, Wuhan, China), *LAMP-2* (Proteintech, Wuhan, China) and *SQSTM1* (Proteintech, Wuhan, China).

Immunofluorescence

After cell fixation, the cells were treated with 0.2% Triton X-100 at room temperature. The cells were then blocked with blocking solution. Subsequently, the cells were treated with primary and secondary antibodies. DAPI dye was added to the cells, which were subsequently incubated in the dark. The cells were mounted on slides using anti-fade mounting medium, and fluorescence was observed using a fluorescence microscope. The antibodies used were against *LC3* (Proteintech, Wuhan, China) and *LAMP-2* (Proteintech, Wuhan, China).

Transmission electron microscopy

The specimens were cut and fixed in a 2.5% glutaraldehyde solution with Millonig's phosphate buffer (pH = 7.3). The samples were washed three times with Millonig's phosphate buffer at 10-minute intervals. The dehydration process was performed at room temperature using a graded series of acetone (50%, 70%, and 90%) at 10-min intervals, followed by two washes with 100% acetone at 15-min intervals. The samples were then soaked and embedded in a mixture of acetone and resin (1:1) for 12 h, followed by polymerization overnight at 37 °C using 100% resin. To solidify the sample resin, the specimens were further polymerized at 37 °C overnight, followed by an additional 12 h at 60 °C. Ultrathin sections of 50-100 nm were obtained from the specimens using an ultramicrotome and a diamond knife. The sections were then stained with 3% uranyl acetate and lead nitrate, after which they were examined and photographed using a Hitachi HT-7700 electron microscope.

M⁶A RNA binding protein immunoprecipitation assay

The M⁶A RNA binding protein immunoprecipitation kit was purchased from RiboBio. RNA was fragmented using RNA fragmentation buffer. Magnetic beads for m⁶A were prepared using magnetic beads A/G and an anti-m⁶A antibody. RNA immunoprecipitation was conducted by mixing the fragmented RNA with anti-m⁶A magnetic beads. The RNA was washed with elution buffer to remove it from the magnetic beads.

Table 1 Primer sequences for qPCR

Genes	Sequence
ALKBH5	Forward 5'- CTTTGCTTCGGCTGCAAGTT -3' Reverse 5'- CCGGCGTTCCTTAATGTCCT -3'
ZKSCAN3	Forward 5'- CAGAGTAGGGTGGAAGCC -3' Reverse 5'- AAGGTATGAAGGTCGGGTG -3'
Primer 1	Forward 5'- CCAGGCGGTCTATTGC -3' Reverse 5'- TGGCTTCCACCCTACTCT -3'
Primer 2	Forward: 5'- CAGAGTAGGGTGGAAGCC-3' Reverse 5'- AGGTATGAAGGTCGGGTG-3'
Primer 3	Forward 5'- TGGTTCGGGATGGCTAG-3' Reverse 5'- AACAGCACTGCCTTGGAG-3'
β -actin	Forward 5'- GTGGCCGAGGACTTIGATTG-3' Reverse 5'- CCTGTAAACAACGCATCTCATATT-3'

Website for m⁶A site prediction

Potential m⁶A binding sites on ZKSCAN3 mRNA were analyzed *via* a website (<http://www.cuilab.cn/sramp/>).

Statistical analysis

All the statistical analyses were performed in GraphPad Prism 8. Independent sample *t* tests were used to compare the means of two samples, while one-way ANOVA was used for analyzing and comparing the means of more than two groups of samples. *P* values < 0.05 were considered to indicate statistical significance. The experimental results are presented as the mean \pm SD.

RESULTS**Impaired autophagy in the AP mouse cell model**

To construct a cell model of AP, MPC-83 cells were treated with 10 nM cerulein for 24 h. The levels of amylase and the inflammatory factors IL-1 β , IL-6, and TNF- α in the supernatant were measured *via* ELISA. The results showed that the levels of amylase and inflammatory factors were significantly greater in the cerulein-treated group (Figure 1A and B), indicating that the AP cell model was successfully established.

The expression levels of autophagy-related marker proteins were detected by western blotting, which showed that the ratio of LC3B-II/I was increased in the AP group, indicating an increase in autophagosomes. The expression of LAMP-2 was decreased in the AP groups, indicating impaired lysosomal synthesis. The expression of the selective autophagy receptor SQSTM1 was increased, indicating inhibited substrate degradation (Figure 1C). Transmission electron microscopy (TEM) revealed the accumulation of circular autophagic vacuoles in the AP group, indicating impaired degradation and accumulation of autophagosomes and autolysosomes (Figure 1D). Furthermore, immunofluorescence staining revealed that LC3 was significantly increased in the AP groups (Figure 1E), while LAMP-2 expression was decreased (Figure 1F). These results demonstrated that autophagosome formation is activated, while lysosomal synthesis and function are impaired, leading to decreased substrate degradation efficiency and accumulation of autophagic vacuoles, suggesting impaired autophagy.

ZKSCAN3 is upregulated and promotes the release of inflammatory factors in AP

To investigate the role of ZKSCAN3 in AP, qPCR, and western blot were used to detect the expression levels of ZKSCAN3. The results showed that the mRNA and protein expression levels of ZKSCAN3 were significantly increased in the AP group (Figure 2A and B). Three different siRNAs were used to knock down the expression of ZKSCAN3, and siRNA-2 had the most significant interference effect (Figure 2C and D). Subsequent experiments were performed using siRNA-2 to knock down ZKSCAN3. After the inhibition of ZKSCAN3, the cells were treated with cerulein to construct the AP cell model. The levels of inflammatory factors IL-1 β , IL-6, and TNF- α in the knocking down (KD) group were significantly lower than those in the negative control (NC) group (Figure 2E). These results suggest that ZKSCAN3 is upregulated and promotes the release of inflammatory factors in the AP mouse cell model.

ZKSCAN3 impaired autophagic flux in AP

To investigate the role of ZKSCAN3 in autophagic flux in AP, western blot was used to detect the expression of autophagy marker proteins (Figure 3A). The LC3B-II/I ratio was decreased in the KD group, demonstrating the increased




Figure 1 Impaired autophagy in a mouse acute pancreatitis cell model. A: The levels of amylase in the supernatant were detected by ELISA; B: The levels of inflammatory factors in the supernatant were detected by ELISA; C: The expression of autophagy-related proteins was detected by western blot; D: The microstructure of intracellular autophagy was observed by transmission electron microscopy; E: The expression of LC3 was detected by immunofluorescence (magnification $\times 800$); F: The expression of LAMP-2 was detected by immunofluorescence (magnification $\times 800$). ^a $P < 0.05$ vs saline group. TNF: Tumor necrosis factor; IL: Interleukin.




Figure 2 The expression and function of ZKSCAN3 in acute pancreatitis. A: The expression of ZKSCAN3 mRNA was detected by qPCR; B: The expression level of ZKSCAN3 protein was detected by western blot; C: The expression level of ZKSCAN3 mRNA treated with three different siRNAs was detected by qPCR; D: The expression level of ZKSCAN3 protein in the MPC-83 cell line treated with three different siRNAs; E: After interfering with the expression of ZKSCAN3, the expression level of inflammatory factors in the mouse acute pancreatitis cell model was detected by ELISA. ^a $P < 0.05$ vs saline group; ^b $P < 0.05$ vs negative control group; ^c $P < 0.05$ vs cerulein group. NC: Negative control. TNF: Tumor necrosis factor; IL: Interleukin.




Figure 3 ZKSCAN3 inhibits autophagic flux in acute pancreatitis. A: The expression of autophagy related proteins in the negative control group and knockdown group was detected by western blot; B: The extent of autophagy was observed by transmission electron microscopy; C: The expression of LC3 was detected by immunofluorescence (magnification $\times 800$); D: The expression of LAMP-2 was detected by immunofluorescence (magnification $\times 800$).

clearance of autophagolysosomes. The expression of *LAMP-2* increased, suggesting a reduction in lysosomal biogenesis impairment, and the expression of *SQSTM1* decreased, indicating an improvement in substrate degradation efficiency. TEM revealed a significant reduction in autophagosome accumulation in the KD group (Figure 3B). Immunofluorescence staining revealed decreased expression of LC3 in the KD group (Figure 3C) and increased expression of LAMP-2 (Figure 3D). These results suggest that ZKSCAN3 inhibits autophagic flux in AP and that KD ZKSCAN3 expression can impair the blockade of autophagic flux.

***ALKBH5* is upregulated in AP and promotes the release of inflammatory factors**

*m*⁶A methylation is widely involved in autophagy and contributes to the pathogenesis of human disease. The expression and function of *ALKBH5*, a primary *m*⁶A demethylase in AP, have not yet been determined. We detected *ALKBH5* expression in the AP mouse cell model by qPCR and western blot analysis. The level of *ALKBH5* was upregulated in the AP mouse cell model (Figure 4A and B). Furthermore, three different siRNAs were used to knock down *ALKBH5* expression in MPC-83 cells, and siRNA-3 had the most effective interference effect (Figure 4C and D); therefore, siRNA-3 was used for subsequent experiments. The expression of the inflammatory factors IL-1 β , IL-6, and TNF- α was significantly reduced (Figure 4E). These results suggest that *ALKBH5* was upregulated in the mouse AP cell model and promoted the release of inflammatory factors.

***ALKBH5* inhibited autophagic flux by promoting ZKSCAN3 expression**

In the AP mouse cell model, knockdown of *ALKBH5* downregulated the mRNA and protein expression of ZKSCAN3 (Figure 5A), indicating that *ALKBH5* promotes ZKSCAN3 expression. Furthermore, the expression of LC3B-II/I and *SQSTM1* decreased, while *LAMP-2* expression was increased (Figure 5B), indicating that the knockdown of *ALKBH5* rescued the blockade of autophagic flux in AP. TEM confirmed that autophagic vacuole accumulation was reduced after the expression of *ALKBH5* was inhibited (Figure 5C). Immunofluorescence revealed that the immunoreactivity of the LC3 protein decreased (Figure 5D), while the immunoreactivity of the LAMP-2 protein increased in the AP mouse cell model transfected with the *ALKBH5* target siRNA (Figure 5E). These results suggested that *ALKBH5* promoted ZKSCAN3 expression, resulting in the blockade of autophagic flux in AP.

***ALKBH5* regulated ZKSCAN3 expression in a *m*⁶A-dependent manner**

Considering that *ALKBH5* is a well-known *m*⁶A demethylase, we further investigated the role of *m*⁶A modification in the regulation of ZKSCAN3 by *ALKBH5*. Biological software analysis revealed 23 potential *m*⁶A binding sites on ZKSCAN3 mRNA, including 6 highly credible sites, 7 highly credible sites, 6 moderately credible sites, and 4 sites with low credibility (Table 2, Figure 6A). Additionally, we constructed a secondary structure diagram of highly credible *m*⁶A binding sites (Figure 6B).

To confirm the role of *m*⁶A modification in the relationship between *ALKBH5* and ZKSCAN3, MeRIP-qPCR was performed with specific primers aimed at identifying potential *m*⁶A sites, and the enrichment of *m*⁶A-modified ZKSCAN3

Table 2 m⁶A sites of *ZKSCAN3* mRNA

Number	Position	Sequence context	Confidence
1	34	GUGCCCCGCCCCCGGGGUCGACUUUCGACACUUUUGUGACUGC	High
2	131	ACAGCUACAGUGAAACGGGAGAACUGCUUGGUUCGGGAUGGCUAG	High
3	180	UCAAGGGAAAGCACAACCUUGGACUCACACUCUGCAGAGGACCAG	Very high
4	198	UUGGACUCACACUCUGCAGAGGACCAGAUGGAGCUACUGGUCAUA	High
5	229	AGCUACUGGUCAUAAAGGUGGAACAAGAAGAGGCCUCCCCUUGG	Moderate
6	534	GUGGCGCUGCUGGAGUACUUGGACAGGCAGCUGGAUGACACACCU	High
7	589	CAGAUGAUGACGAUGGGCAGGAACUCCUUUGCUCCAAGGCAGUGC	Moderate
8	824	CCCAGUCCUUUCCCCCAGAUGGACAGAGCAGGAUUAUCUCAGAU	Very high
9	849	GAGCAGGAUUAUCUCAGAUGAACUCUACAAAGAUGGAAUGCAG	Moderate
10	906	AGCCUGGUUUCCUGGAUCAGGACAUGCAGACUAAGGUUAGGGAC	Very high
11	914	UUCCCUGGAUCAGGACAUGCAGACUAAGGUUAGGGACUUGCCUCG	Moderate
12	927	GACAUGCAGACUAAGGUUAGGGACUUGCCUCGAGCUGAAGAAUAC	Very high
13	954	CCUCGAGCUGAAGAAUACAGGGACCAAAAGCCUGAGCAGACAGUG	High
14	971	CAGGGACCAAAAGCCUGAGCAGACAGUGUGCUUCCUGGGUGAAGA	Low
15	993	ACAGUGUGCUUCCUGGGUGAAGACACUGUCCCGAUUCCUACAGGU	Low
16	1347	GAAAAGCCCUACGAGUGUGAUGACUGUGGGAAAACCUUCACUCAG	High
17	1387	CUCAGAGCUGCAGCCUCCUUGAACAUACAGAAUUCACACUGGGG	Low
18	1471	GGCGUAGCUCACAUCUUCUGAGACAUCAGAGGACCAUACUGGGG	Moderate
19	1633	GUAGGAUUACAAGCCUUAUUGAACACCAAAAAGUACACACUGGUG	Low
20	1745	GAGAAGACACACGGGGAAGAAAACUUCUGUCACAGUGACCCUGC	Moderate
21	1803	GUUGGUGUUAACUGUCAUUGAACUGAAGCCACUCUGUAGUUCUU	High
22	1830	AGCCACUCUGUAGUUCUUAUGACUGCAGAAGUCAUAGGCUGGGG	Very high
23	1985	ACAAGAGUCCUCACCCAUUGGAACUAAAUGGGCUUCCUGACUGUC	Very high

mRNA in the AP group was significantly lower (Figure 7). This finding suggested that *ALKBH5* can decrease the m⁶A modification of *ZKSCAN3*.

DISCUSSION

This study is the first to reveal the regulatory roles of *ZKSCAN3* and m⁶A modification in impairing autophagy in AP. We found that *ALKBH5* upregulated *ZKSCAN3* expression by demethylating *ZKSCAN3* inhibited autophagy, and promoted the release of inflammatory factors in a mouse cell model of AP.

Impaired autophagy is one of the key pathogenic mechanisms in AP; this process affects the functions of various organelles, such as mitochondria and the endoplasmic reticulum, and disrupts the homeostasis of acinar cells[12,25]. Usually, autophagy degrades dysfunctional mitochondria during AP. Inhibition of autophagic flux by knocking out the *ATG5* and *ATG7* genes impaired the clearance of damaged mitochondria, further affecting generation the efficiency of ATP generation in acinar cells[26,27]. Moreover, autophagy maintains the stability of endoplasmic reticulum function. Knocking out the IκB kinase α gene leads to impaired autophagy, and the accumulated *SQSTM1* further causes the accumulation of misfolded proteins in the endoplasmic reticulum, triggering endoplasmic reticulum stress and ultimately inducing AP[28]. Therefore, impaired autophagy may trigger or exacerbate other cellular pathological factors in AP. Furthermore, other pathological factors can also induce impaired autophagy. In arginine-treated mice, abnormal mitochondrial membrane leads to disrupted energy metabolism, which inhibits autophagic flux[29]. In ethanol-induced AP, endoplasmic reticulum stress causes folding and transport disorders of autophagy-related proteins[30]. Therefore, autophagy is interconnected with other pathological events during AP. Early autophagy-related intervention may help alleviate the malignant cycle caused by pathological factors.

ZKSCAN3 is currently recognized as a key autophagy inhibitor[15,31]. It affects the progression of various diseases by inhibiting autophagic flux. In hepatocellular carcinoma (HCC), *ZKSCAN3* inhibits autophagy, leading to decreased degradation of local adhesion proteins and reducing the metastasis of HCC[32]. In addition, impaired autophagy




Figure 4 The expression and function of *ALKBH5* in acute pancreatitis. A: qPCR was used to detect *ALKBH5* mRNA expression in acute pancreatitis (AP) group and control group; B: The expression level of the *ALKBH5* protein in AP group and control group was detected by western blot; C: qPCR was used to detect *ALKBH5* mRNA expression in the MPC-83 cell line treated with different siRNAs; D: western blot was used to detect *ALKBH5* protein expression in MPC-83 cell line treated with three different siRNA; E: After interfering with the expression of *ALKBH5*, the expression level of inflammatory factors in the mouse AP cell line was detected by ELISA. ^a $P < 0.05$ vs saline group; ^b $P < 0.05$ vs negative control group; ^c $P < 0.05$ vs cerulein group. NC: Negative control; TNF: Tumor necrosis factor; IL: Interleukin.




Figure 5 *ALKBH5* promoted the expression of *ZKSCAN3* and inhibited autophagic flux. A: After interfering with *ALKBH5* expression, the expression level of *ZKSCAN3* mRNA was detected by qPCR; B: The expression levels of *ZKSCAN3* protein and autophagy related proteins were detected by western blot; C: Autophagic microstructure was observed by transmission electron microscopy; D: LC3 was detected by immunofluorescence (magnification $\times 800$); E: LAMP-2 was detected by immunofluorescence (magnification $\times 800$). ^a $P < 0.05$ vs negative cerulein group. NC: Negative control.




Figure 6 Prediction of m⁶A binding sites in ZKSCAN3. A: Potential m⁶A binding sites on ZKSCAN3 mRNA were analyzed via a website (<http://www.cuilab.cn/sramp/>); B: Diagram of the secondary structure of highly credible m⁶A binding sites. m⁶A: N⁶-methyladenosine.

mediated by ZKSCAN3 is closely related to sepsis-induced immunosuppression[33]. However, the role of ZKSCAN3 in the pathogenesis of AP is still uncertain. Our study first confirmed the high expression of ZKSCAN3 in cerulein-treated MPC-83 cells and the inhibitory effect on autophagy.

ZKSCAN3 functions mainly through nucleoplasmic translocation; when activated, it moves into the nucleus to suppress the transcription of autophagy related genes[15]. However, the upstream regulatory mechanism of ZKSCAN3 is unclear. A study revealed that SIRT1 deacetylates the lysine residues of ZKSCAN3 and promotes its shuttling between the nucleus and cytoplasm[34]. PKC and BRAF inhibitors can activate the inhibition of ZKSCAN3 via phosphorylation[35,36]. Although a few studies have revealed the upstream molecular mechanisms of ZKSCAN3, there is no related research focusing on this gene in AP.




Figure 7 Enrichment levels of m⁶A modifications on *ZKSCAN3* mRNA. A: qPCR was used to detect the m⁶A modification level of *ZKSCAN3* mRNA; B: Schematic diagram of the sequences of primers used for *ZKSCAN3* mRNA. ^a*P* < 0.05 vs saline group.

As an important component of epigenetics, m⁶A modification plays an important regulatory role in autophagy. METTL3 promotes the binding of the RNA-binding protein HNRNP D to the precursor mRNA of TFEB, thus inhibiting autophagy[23]. In HCC, loss of METTL3 increases the stability of the FOXO3 mRNA 3'-UTR modification through a YTHDF1-dependent mechanism and activates autophagy[37]. Moreover, in testicular stromal cells, human chorionic gonadotropin activates autophagy flow by upregulating the expression of *ALKBH5* and inhibiting the translation of the m⁶A-mediated protein PPM1A, thereby increasing testosterone secretion[38]. Therefore, m⁶A modification is widely involved in the regulation of autophagy in physiological and pathological processes. Among different types of diseases, the same type of m⁶A modification has different effects on autophagy, which is related to downstream molecular targets and the pathological and physiological stages of disease[39]. Currently, the regulatory role of m⁶A modification in autophagy has been well documented in various disorders[40], but its role in AP has rarely been studied. Bioinformatics study has shown that m⁶A-modified noncoding RNAs may participate in the pathological changes observed in AP, but there is still a lack of relevant experimental evidence[24]. This research is the first to demonstrate that *ALKBH5* upregulates the expression of *ZKSCAN3* by demethylation, thereby inhibiting autophagy in AP.

This study has several limitations. First, the experimental subjects were cell models, and further *in vivo* animal experiments need to be conducted. In addition, there are significant differences in homology between animal and human tissues. However, due to the lack of human pancreatic exocrine cell lines and a stable extraction method, experimental research on AP cannot be performed in depth in human tissue[41,42]. In clinical practice, identifying pancreatic, peripancreatic or infected necrotic tissues is difficult due to pancreatic juice corrosion or infection. Therefore, human pancreatic exocrine cell lines and tissues are essential for mechanistic research on AP in the future.

CONCLUSION

In summary, we first revealed the important roles of *ZKSCAN3* and m⁶A modification in AP. In cerulein-treated MPC-83 cells, *ALKBH5* upregulates *ZKSCAN3* expression by demethylation, thereby inhibiting autophagic flux and aggravating the severity of AP. The results obtained in this study provide important insights into the mechanism of autophagy regulation in AP and offer reference value for future in-depth exploration and early intervention.

ARTICLE HIGHLIGHTS

Research background

The incidence of acute pancreatitis (AP) is increasing annually, and its mortality rate is high. Impaired autophagy is a key factor in the occurrence and development of AP. Therefore, it is crucial to clarify the regulatory mechanism of autophagy in AP.

Research motivation

Evidence has shown that *ALKBH5* and *ZKSCAN3* can regulate autophagy in a variety of diseases, but there are no relevant studies on AP.

Research objectives

We aimed to explore the regulatory functions and mechanisms of autophagy mediated by *ALKBH5* and *ZKSCAN3* in AP.

Research methods

The AP mouse cell line was constructed with cerulein, and the levels of inflammatory factors were detected *via* ELISA. Similarly, the expression of *ALKBH5*, *ZKSCAN3* and autophagy-related proteins was detected *via* qPCR, western blot, and immunofluorescence. Microscopic manifestations of autophagy in the cell model were observed *via* transmission electron microscopy. Additionally, RNA binding protein immunoprecipitation was used to analyze the interaction between *ALKBH5* and *ZKSCAN3*.

Research results

The expression of *ALKBH5* and *ZKSCAN3* was upregulated in the AP model, and the trend toward increased expression of autophagy-related genes suggested that autophagic flux was blocked in AP. Autophagy was improved by inhibiting the expression of *ALKBH5* and *ZKSCAN3*. *ZKSCAN3* mRNA has m⁶A binding sites, and *ALKBH5* can upregulate its expression by demethylating *ZKSCAN3*, which inhibits autophagic flux, thereby aggravating inflammation in AP.

Research conclusions

ALKBH5 suppresses autophagic flux by demethylating the m⁶A site on *ZKSCAN3* mRNA, consequently promoting the onset and progression of AP.

Research perspectives

We proved that *ALKBH5* inhibits autophagy by upregulating *ZKSCAN3*, thereby promoting the occurrence and development of AP and providing new ideas for future research on autophagy regulation and early drug intervention in AP.

FOOTNOTES

Co-corresponding authors: Shuai Zhu and Geng-Wen Huang.

Author contributions: Zhu S and Huang GW conceived, designed and refined the study protocol; Zhang T finished the experiments, collected and analyzed the data and drafted the manuscript; Zhu S and Huang GW reviewed and revised the manuscript. All authors had access to the study data and reviewed and approved the final manuscript. Zhu S and Huang GW contributed equally to this work as co-corresponding authors. The reasons for designating Zhu S and Huang GW as co-corresponding authors are twofold. First, co-corresponding authors jointly conceived the overall design of the study and revised the manuscript. Second, they jointly provided financial support for the study. In summary, we believe that designating Zhu S and Huang GW as co-corresponding authors accurately reflects our team's collaborative spirit, equal contributions, and diversity.

Supported by National Natural Science Foundation of China, No. 81802450; and Natural Science Foundation of Hunan Province, No. 2020JJ4133 and No. 2021JJ31135.

Institutional review board statement: The study was reviewed and approved by the Institutional Review Board at Xiangya Hospital of Central South University.

Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Xiangya Hospital of Central South University.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.

Data sharing statement: No additional data are available.

ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Tao Zhang 0000-0002-6409-9746; Shuai Zhu 0000-0002-1250-1350; Geng-Wen Huang 0000-0003-1426-8000.

S-Editor: Qu XL

L-Editor: A

P-Editor: Chen YX

REFERENCES

- 1 Iannuzzi JP, King JA, Leong JH, Quan J, Windsor JW, Tanyingoh D, Coward S, Forbes N, Heitman SJ, Shaheen AA, Swain M, Buie M, Underwood FE, Kaplan GG. Global Incidence of Acute Pancreatitis Is Increasing Over Time: A Systematic Review and Meta-Analysis. *Gastroenterology* 2022; **162**: 122-134 [PMID: 34571026 DOI: 10.1053/j.gastro.2021.09.043]
- 2 Mederos MA, Reber HA, Giris MD. Acute Pancreatitis: A Review. *JAMA* 2021; **325**: 382-390 [PMID: 33496779 DOI: 10.1001/jama.2020.20317]
- 3 Ouyang G, Pan G, Liu Q, Wu Y, Liu Z, Lu W, Li S, Zhou Z, Wen Y. The global, regional, and national burden of pancreatitis in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *BMC Med* 2020; **18**: 388 [PMID: 33298026 DOI: 10.1186/s12916-020-01859-5]
- 4 Saluja A, Dudeja V, Dawra R, Sah RP. Early Intra-Acinar Events in Pathogenesis of Pancreatitis. *Gastroenterology* 2019; **156**: 1979-1993 [PMID: 30776339 DOI: 10.1053/j.gastro.2019.01.268]
- 5 Lee PJ, Papachristou GI. New insights into acute pancreatitis. *Nat Rev Gastroenterol Hepatol* 2019; **16**: 479-496 [PMID: 31138897 DOI: 10.1038/s41575-019-0158-2]
- 6 Wen X, Yang Y, Klionsky DJ. Moments in autophagy and disease: Past and present. *Mol Aspects Med* 2021; **82**: 100966 [PMID: 33931245 DOI: 10.1016/j.mam.2021.100966]
- 7 Mizushima N, Levine B. Autophagy in Human Diseases. *N Engl J Med* 2020; **383**: 1564-1576 [PMID: 33053285 DOI: 10.1056/NEJMr2022774]
- 8 Klionsky DJ, Petroni G, Amaravadi RK, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cadwell K, Cecconi F, Choi AMK, Choi ME, Chu CT, Codogno P, Colombo MI, Cuervo AM, Deretic V, Dikic I, Elazar Z, Eskelinen EL, Fimia GM, Gewirtz DA, Green DR, Hansen M, Jäättelä M, Johansen T, Juhász G, Karantza V, Kraft C, Kroemer G, Ktistakis NT, Kumar S, Lopez-Otin C, Macleod KF, Madeo F, Martinez J, Meléndez A, Mizushima N, Münz C, Penninger JM, Perera RM, Piacentini M, Reggiori F, Rubinshtein DC, Ryan KM, Sadoshima J, Santambrogio L, Scorrano L, Simon HU, Simon AK, Simonsen A, Stolz A, Tavernarakis N, Tooze SA, Yoshimori T, Yuan J, Yue Z, Zhong Q, Galluzzi L, Pietrocola F. Autophagy in major human diseases. *EMBO J* 2021; **40**: e108863 [PMID: 34459017 DOI: 10.15252/embj.2021108863]
- 9 Chen T, Tu S, Ding L, Jin M, Chen H, Zhou H. The role of autophagy in viral infections. *J Biomed Sci* 2023; **30**: 5 [PMID: 36653801 DOI: 10.1186/s12929-023-00899-2]
- 10 Gukovskaya AS, Gukovsky I, Algül H, Habtezion A. Autophagy, Inflammation, and Immune Dysfunction in the Pathogenesis of Pancreatitis. *Gastroenterology* 2017; **153**: 1212-1226 [PMID: 28918190 DOI: 10.1053/j.gastro.2017.08.071]
- 11 Wang S, Ni HM, Chao X, Wang H, Bridges B, Kumer S, Schmitt T, Mareninova O, Gukovskaya A, De Lisle RC, Ballabio A, Pacher P, Ding WX. Impaired TFEB-mediated lysosomal biogenesis promotes the development of pancreatitis in mice and is associated with human pancreatitis. *Autophagy* 2019; **15**: 1954-1969 [PMID: 30894069 DOI: 10.1080/15548627.2019.1596486]
- 12 Yuan X, Wu J, Guo X, Li W, Luo C, Li S, Wang B, Tang L, Sun H. Autophagy in Acute Pancreatitis: Organelle Interaction and microRNA Regulation. *Oxid Med Cell Longev* 2021; **2021**: 8811935 [PMID: 33628384 DOI: 10.1155/2021/8811935]
- 13 Saftig P, Haas A. Turn up the lysosome. *Nat Cell Biol* 2016; **18**: 1025-1027 [PMID: 27684505 DOI: 10.1038/ncb3409]
- 14 Füllgrabe J, Ghislat G, Cho DH, Rubinshtein DC. Transcriptional regulation of mammalian autophagy at a glance. *J Cell Sci* 2016; **129**: 3059-3066 [PMID: 27528206 DOI: 10.1242/jcs.188920]
- 15 Chauhan S, Goodwin JG, Chauhan S, Manyam G, Wang J, Kamat AM, Boyd DD. ZKSCAN3 is a master transcriptional repressor of autophagy. *Mol Cell* 2013; **50**: 16-28 [PMID: 23434374 DOI: 10.1016/j.molcel.2013.01.024]
- 16 Pan H, Yan Y, Liu C, Finkel T. The role of ZKSCAN3 in the transcriptional regulation of autophagy. *Autophagy* 2017; **13**: 1235-1238 [PMID: 28581889 DOI: 10.1080/15548627.2017.1320635]
- 17 Liang J, Sun J, Zhang W, Wang X, Xu Y, Peng Y, Zhang L, Xiong W, Liu Y, Liu H. Novel Insights into The Roles of N(6)-methyladenosine (m(6)A) Modification and Autophagy in Human Diseases. *Int J Biol Sci* 2023; **19**: 705-720 [PMID: 36632456 DOI: 10.7150/ijbs.75466]
- 18 Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. *Nat Rev Mol Cell Biol* 2019; **20**: 608-624 [PMID: 31520073 DOI: 10.1038/s41580-019-0168-5]
- 19 Qu J, Yan H, Hou Y, Cao W, Liu Y, Zhang E, He J, Cai Z. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential. *J Hematol Oncol* 2022; **15**: 8 [PMID: 35063010 DOI: 10.1186/s13045-022-01224-4]
- 20 Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, Yang C, Chen Y. The role of m6A modification in the biological functions and diseases. *Signal Transduct Target Ther* 2021; **6**: 74 [PMID: 33611339 DOI: 10.1038/s41392-020-00450-x]
- 21 Zhu H, Gan X, Jiang X, Diao S, Wu H, Hu J. ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2. *J Exp Clin Cancer Res* 2019; **38**: 163 [PMID: 30987661 DOI: 10.1186/s13046-019-1159-2]
- 22 Yin H, Gu P, Xie Y, You X, Zhang Y, Yao Y, Yang S, Wang D, Chen W, Ma J. ALKBH5 mediates silica particles-induced pulmonary inflammation through increased m(6)A modification of Slamf7 and autophagy dysfunction. *J Hazard Mater* 2024; **462**: 132736 [PMID: 37827106 DOI: 10.1016/j.jhazmat.2023.132736]
- 23 Song H, Feng X, Zhang H, Luo Y, Huang J, Lin M, Jin J, Ding X, Wu S, Huang H, Yu T, Zhang M, Hong H, Yao S, Zhao Y, Zhang Z. METTL3 and ALKBH5 oppositely regulate m(6)A modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes. *Autophagy* 2019; **15**: 1419-1437 [PMID: 30870073 DOI: 10.1080/15548627.2019.1586246]
- 24 Wu J, Yuan XH, Jiang W, Lu YC, Huang QL, Yang Y, Qie HJ, Liu JT, Sun HY, Tang LJ. Genome-wide map of N(6)-methyladenosine circular RNAs identified in mice model of severe acute pancreatitis. *World J Gastroenterol* 2021; **27**: 7530-7545 [PMID: 34887647 DOI: 10.3748/wjg.v27.i43.7530]
- 25 Voronina S, Chvanov M, De Faveri F, Mayer U, Wileman T, Criddle D, Tepikin A. Autophagy, Acute Pancreatitis and the Metamorphoses of a Trypsinogen-Activating Organelle. *Cells* 2022; **11** [PMID: 36010591 DOI: 10.3390/cells11162514]

- 26 **Shirihai OS**, Song M, Dorn GW 2nd. How mitochondrial dynamism orchestrates mitophagy. *Circ Res* 2015; **116**: 1835-1849 [PMID: 25999423 DOI: 10.1161/CIRCRESAHA.116.306374]
- 27 **Diakopoulos KN**, Lesina M, Wörmann S, Song L, Aichler M, Schild L, Artati A, Römisch-Margl W, Wartmann T, Fischer R, Kabiri Y, Zischka H, Halangk W, Demir IE, Pilsak C, Walch A, Mantzoros CS, Steiner JM, Erkan M, Schmid RM, Witt H, Adamski J, Algül H. Impaired autophagy induces chronic atrophic pancreatitis in mice *via* sex- and nutrition-dependent processes. *Gastroenterology* 2015; **148**: 626-638.e17 [PMID: 25497209 DOI: 10.1053/j.gastro.2014.12.003]
- 28 **Li N**, Wu X, Holzer RG, Lee JH, Todoric J, Park EJ, Ogata H, Gukovskaya AS, Gukovsky I, Pizzo DP, VandenBerg S, Tarin D, Atay C, Arkan MC, Deerinck TJ, Moscat J, Diaz-Meco M, Dawson D, Erkan M, Kleeff J, Karin M. Loss of acinar cell IKK α triggers spontaneous pancreatitis in mice. *J Clin Invest* 2013; **123**: 2231-2243 [PMID: 23563314 DOI: 10.1172/JCI64498]
- 29 **Biczo G**, Vegh ET, Shalbueva N, Mareninova OA, Elperin J, Lotshaw E, Gretler S, Lugea A, Malla SR, Dawson D, Ruchala P, Whitelegge J, French SW, Wen L, Husain SZ, Gorelick FS, Hegyi P, Rakonczay Z Jr, Gukovsky I, Gukovskaya AS. Mitochondrial Dysfunction, Through Impaired Autophagy, Leads to Endoplasmic Reticulum Stress, Deregulated Lipid Metabolism, and Pancreatitis in Animal Models. *Gastroenterology* 2018; **154**: 689-703 [PMID: 29074451 DOI: 10.1053/j.gastro.2017.10.012]
- 30 **Lugea A**, Waldron RT, French SW, Pandol SJ. Drinking and driving pancreatitis: links between endoplasmic reticulum stress and autophagy. *Autophagy* 2011; **7**: 783-785 [PMID: 21460613 DOI: 10.4161/auto.7.7.15594]
- 31 **Hu H**, Ji Q, Song M, Ren J, Liu Z, Wang Z, Liu X, Yan K, Hu J, Jing Y, Wang S, Zhang W, Liu GH, Qu J. ZKSCAN3 counteracts cellular senescence by stabilizing heterochromatin. *Nucleic Acids Res* 2020; **48**: 6001-6018 [PMID: 32427330 DOI: 10.1093/nar/gkaa425]
- 32 **Zhang X**, Bai Y, Huang L, Liu S, Mo Y, Cheng W, Wang G, Cao Z, Chen X, Cui H, Qi L, Ma L, Liu M, Guan XY, Ma NF. CHD1L augments autophagy-mediated migration of hepatocellular carcinoma through targeting ZKSCAN3. *Cell Death Dis* 2021; **12**: 950 [PMID: 34654797 DOI: 10.1038/s41419-021-04254-x]
- 33 **Ouyang X**, Becker E Jr, Bone NB, Johnson MS, Craver J, Zong WX, Darley-Usmar VM, Zmijewski JW, Zhang J. ZKSCAN3 in severe bacterial lung infection and sepsis-induced immunosuppression. *Lab Invest* 2021; **101**: 1467-1474 [PMID: 34504306 DOI: 10.1038/s41374-021-00660-z]
- 34 **Wu X**, Ren Y, Wen Y, Lu S, Li H, Yu H, Li W, Zou F. Deacetylation of ZKSCAN3 by SIRT1 induces autophagy and protects SN4741 cells against MPP(+)-induced oxidative stress. *Free Radic Biol Med* 2022; **181**: 82-97 [PMID: 35124181 DOI: 10.1016/j.freeradbiomed.2022.02.001]
- 35 **Li Y**, Xu M, Ding X, Yan C, Song Z, Chen L, Huang X, Wang X, Jian Y, Tang G, Tang C, Di Y, Mu S, Liu X, Liu K, Li T, Wang Y, Miao L, Guo W, Hao X, Yang C. Protein kinase C controls lysosome biogenesis independently of mTORC1. *Nat Cell Biol* 2016; **18**: 1065-1077 [PMID: 27617930 DOI: 10.1038/ncb3407]
- 36 **Li S**, Song Y, Quach C, Guo H, Jang GB, Maazi H, Zhao S, Sands NA, Liu Q, In GK, Peng D, Yuan W, Machida K, Yu M, Akbari O, Hagiya A, Yang Y, Punj V, Tang L, Liang C. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. *Nat Commun* 2019; **10**: 1693 [PMID: 30979895 DOI: 10.1038/s41467-019-09634-8]
- 37 **Lin Z**, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, Zhang X, Bu X, He W, Wan G. RNA m(6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. *EMBO J* 2020; **39**: e103181 [PMID: 32368828 DOI: 10.15252/embj.2019103181]
- 38 **Chen Y**, Wang J, Xu D, Xiang Z, Ding J, Yang X, Li D, Han X. m(6)A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells. *Autophagy* 2021; **17**: 457-475 [PMID: 31983283 DOI: 10.1080/15548627.2020.1720431]
- 39 **Ma Q**, Long S, Gan Z, Tettamanti G, Li K, Tian L. Transcriptional and Post-Transcriptional Regulation of Autophagy. *Cells* 2022; **11** [PMID: 35159248 DOI: 10.3390/cells11030441]
- 40 **Füllgrabe J**, Klionsky DJ, Joseph B. The return of the nucleus: transcriptional and epigenetic control of autophagy. *Nat Rev Mol Cell Biol* 2014; **15**: 65-74 [PMID: 24326622 DOI: 10.1038/nrm3716]
- 41 **Case RM**. Is the rat pancreas an appropriate model of the human pancreas? *Pancreatol* 2006; **6**: 180-190 [PMID: 16534243 DOI: 10.1159/000091849]
- 42 **Saloman JL**, Albers KM, Cruz-Monserrate Z, Davis BM, Edderkaoui M, Eibl G, Epouhe AY, Gedeon JY, Gorelick FS, Grippo PJ, Groblewski GE, Husain SZ, Lai KKY, Pandol SJ, Uc A, Wen L, Whitcomb DC. Animal Models: Challenges and Opportunities to Determine Optimal Experimental Models of Pancreatitis and Pancreatic Cancer. *Pancreas* 2019; **48**: 759-779 [PMID: 31206467 DOI: 10.1097/MPA.0000000000001335]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

